ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...
Pause of enrollment limited to US sites in ENIGMA-TRS 2; Global ENIGMA-TRS 1 study continues with over 400 patients enrolled Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果